Fraud prevention month. A new industry initiative and a Manulife first

March 15, 2023

For business owners, plan sponsors and administrators

On March 1, the first day of Fraud Prevention Month 2023, the Canadian Life and Health Insurance Association launched a new initiative aimed at greatly improving the industry’s ability to investigate the misuse of benefits plan coverage.
 

The Joint Provider Fraud Investigation initiative will see all participating carriers, including Manulife, collaborate to conduct joint investigations into suspicious claims activities by providers.

“Rather than each impacted carrier performing their own independent investigations, the shared expertise and resources of all participating carriers can be called on to determine the appropriate next steps,” says Alanna Rand, Assistant Vice-president of Group Benefits Operations Integrity at Manulife.

“This is a really significant step forward for the industry, and for all plan sponsors and covered individuals regardless of which carrier provides their benefits plans,” says Rand. “And Manulife is thrilled to have been the very first carrier to initiate an investigation through the new program.”

This announcement builds on an industry program, announced in 2022, that uses Artificial Intelligence to help identify fraudulent activity across a vast pool of anonymized claims data. The Joint Provider Fraud Investigation program does not share personally identifiable information about plan members, and investigative evidence is held securely and can only be accessed by carriers who have joined the investigation.

Related links:

Manulife’s optimized drug formulary offers improved drug plan cost controls

We’re combining four of our most effective drug plan management solutions in one package – to help sponsors optimize savings & provide members with access to the medications they need.

Group Benefits industry news

Saskatchewan Biosimilar Initiative

Action required for members on biologics. Saskatchewanians using certain biologic drugs will need to switch to the biosimilar version by April 30, 2023. Read here to learn more about the change.

Group Benefits industry news